A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204) by Churchyard, Gavin J. et al.
A Phase IIA Randomized Clinical Trial of a Multiclade HIV-
1 DNA Prime Followed by a Multiclade rAd5 HIV-1
Vaccine Boost in Healthy Adults (HVTN204)
Gavin J. Churchyard
1,2*, Cecilia Morgan
3, Elizabeth Adams
4, John Hural
3, Barney S. Graham
5, Zoe
Moodie
3, Doug Grove
3, Glenda Gray
6, Linda-Gail Bekker
7, M. Juliana McElrath
3, Georgia D. Tomaras
8,
Paul Goepfert
9, Spyros Kalams
10, Lindsey R. Baden
11, Michelle Lally
12, Raphael Dolin
13, William
Blattner
14, Artur Kalichman
15, J. Peter Figueroa
16, Jean Pape
17, Mauro Schechter
18, Olivier Defawe
3,
Stephen C. De Rosa
3, David C. Montefiori
19, Gary J. Nabel
5, Lawrence Corey
3, Michael C. Keefer
20, and
the NIAID HIV Vaccine Trials Network
1Aurum Institute for Health Research, Klerksdorp, South Africa, 2Centre for AIDS Programme of Research in South Africa (CAPRISA), University of Kwa-Zulu Natal, Durban,
South Africa, 3Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, 4Division of
AIDS,National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Health (NIH), Bethesda, Maryland, United States of America,5Vaccine Research Center,
NIAID, NIH, Bethesda, Maryland, United States of America, 6Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa, 7Desmond Tutu HIV
Foundation, University of Cape Town, Cape Town, South Africa, 8Duke University Medical Center, Durham, North Carolina,United States of America,9University of Alabama,
Birmingham, Alabama, United States of America, 10Vanderbilt University, Nashville, Tennessee, United States of America, 11Harvard-Brigham and Women’s Hospital,
Boston, Massachusetts, United States of America, 12Alpert Medical School of Brown University and Miriam Hospital, Providence, Rhode Island, United States of America,
13HarvardMedicalSchool-BethIsraelDeaconessMedical Center,Boston, Massachusetts, UnitedStates ofAmerica,14UniversityofMaryland, CollegePark, Maryland,United
States of America, 15Centro de Referencia e Treinamento em DST/AIDS, Coordenacao dos Institutos de Pesquisa, San Paulo, Brazil, 16Epidemiology Research and Training
Unit (ERTU), Kingston, Jamaica, 17Cornell-GHESKIO, Institut National de Laboratoire et de Recherches, Port au Prince, Haiti, 18Projeto Prac ¸a Onze, Hospital Escola Sa ˜o
Francisco de Assis, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 19Duke Human Vaccine Institute, School of Medicine, Duke University, Durham, North
Carolina, United States of America, 20Department of Medicine, University of Rochester School of Medicine & Dentistry, Rochester, New York, United States of America
Abstract
Background: The safety and immunogenicity of a vaccine regimen consisting of a 6-plasmid HIV-1 DNA prime (envA, envB,
envC, gagB, polB, nefB) boosted by a recombinant adenovirus serotype-5 (rAd5) HIV-1 with matching inserts was evaluated
in HIV-seronegative participants from South Africa, United States, Latin America and the Caribbean.
Methods: 480 participants were evenly randomized to receive either: DNA (4 mg IM by Biojector) at 0, 1 and 2 months,
followed by rAd5 (10
10 PU IM by needle/syringe) at 6 months; or placebo. Participants were monitored for reactogenicity
and adverse events throughout the 12-month study. Peak and duration of HIV-specific humoral and cellular immune
responses were evaluated after the prime and boost.
Results: The vaccine was well tolerated and safe. T-cell responses, detected by interferon-c (IFN-c) ELISpot to global
potential T-cell epitopes (PTEs) were observed in 70.8% (136/192) of vaccine recipients overall, most frequently to Gag
(54.7%) and to Env (54.2%). In U.S. vaccine recipients T-cell responses were less frequent in Ad5 sero-positive versus sero-
negative vaccine recipients (62.5% versus 85.7% respectively, p=0.035). The frequency of HIV-specific CD4+ and CD8+ T-cell
responses detected by intracellular cytokine staining were similar (41.8% and 47.2% respectively) and most secreted $2
cytokines. The vaccine induced a high frequency (83.7%–94.6%) of binding antibody responses to consensus Group M, and
Clades A, B and C gp140 Env oligomers. Antibody responses to Gag were elicited in 46% of vaccine recipients.
Conclusion: The vaccine regimen was well-tolerated and induced polyfunctional CD4+ and CD8+ T-cells and multi-clade
anti-Env binding antibodies.
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Introduction
Control of the HIV pandemic is a major global health priority
and it is likely that the development of a safe and effective vaccine
to prevent HIV infection and/or HIV-related disease will be
needed to achieve this goal [1]. Results from a recently reported
phase III study of a combination vaccine regimen conducted in
Thailand (RV144) by the Thai Ministry of Public Health and the
U.S. Military HIV Research Program has created optimism that a
preventive vaccine can be developed, although the efficacy of that
regimen was judged to be marginal, short-lived and not sufficient
to be useful at a population level [2]. The RV144 regimen
consisted of canarypox HIV-gag/protease/envelope boosted by
rgp120 B/E protein and produced strong anti-gp120 binding
antibodies and T-cell help as demonstrated by lymphoprolifera-
tion. It is anticipated that data from this study can provide a
framework to inform the development of new vaccine approaches.
A major obstacle to the development of a highly effective
vaccine regimen is posed by the marked genetic diversity among
global HIV-1 isolates, which is more pronounced in the viral
envelope than the internal structural and regulatory proteins [3].
One approach to address viral diversity has been to include
immunogens from multiple HIV-1 subtypes in the candidate
vaccine preparation. The Dale and Betty Bumpers Vaccine
Research Center (VRC) at the U.S. National Institute of Allergy
and Infectious Diseases (NIAID) has employed this strategy in the
development of a combination vaccine regimen consisting of a 6-
plasmid DNA vaccine boosted with a 4-component replication-
defective recombinant adenovirus serotype 5 (rAd5) vectors; genes
encoding Envelope proteins from subtypes A, B, and C, and a
Gag-Pol fusion protein from subtype B are included in each
vaccine, and the DNA, but not the rAd5, encodes Nef from
subtype B [4,5,6,7,8]. This regimen has shown promise in SIV
challenge studies of a nonhuman primate model, has been shown
to be safe and immunogenic in phase I studies and is currently
being evaluated for vaccine activity [9,10].
The objectives of this phase II clinical trial were to evaluate the
safety and immunogenicity of the VRC multiclade DNA-HIV
prime/rAd5-HIV boost in HIV-1 uninfected healthy adult
participants at NIAID HIV Vaccine Trials Network (HVTN)
clinical research sitesinthe Americas (UnitedStates, Haiti,Jamaica,
and Brazil) and South Africa. The study was conducted in diverse
geographic regions in order to evaluate safety and immunogenicity
in settings with different circulating HIV clades and prevalence of
pre-existingAd5immunity.Thisstudyisthelargestofthreephase II
trials evaluating the same vaccine regimen. The two other trials
were conducted in sub-Saharan Africa only: one funded and
implemented by the U.S. Military HIV Research Program
(USMHRP protocol RV172) [11] and the other by the Interna-
tional AIDS Vaccine Initiative (IAVI protocol V001) [12]. Our
report will provide additional safety and immunogenicity data not
evaluated in the RV172 and IAVI V001 clinical trials.
Methods
Ethics statement
The study protocol was approved by institutional review
boards at each of the participating sites: Universidade Federal do
Rio de Janeiro, Hospital Universita ´rio Clementino Fraga Filho
Faculdade de Medicina for the Rio, Brazil site; Secretaria de
Estado da Sau ´de, Coordenadoria de Controle de Doenc ¸as
Centro de Refere ˆncia e Treinamento DST/AIDS for the Sao
Paulo, Brazil site; Comite ´ des Droits Humains des Centres
GHESKIO; Ministe `re de la Sante ´ Publique et de la Population
National Ethics Committee and Weill Cornell Medical College,
Human Research Protection Programs, Division of Research
Integrity for the Port au Prince, Haiti site; Ministry of Health and
Environment, Standards & Regulations Division; University of
the West Indies Ethics Committee for the Kingston site;
University of Alabama at Birmingham IRB for the Birmingham,
AL site; Partners Human Research Committee for the Boston,
MA (Brigham & Women’s) site; Miriam Hospital, Office of
Research Administration Communications and Committee
Review for the Providence, RI site; Vanderbilt IRB for the
Nashville, TN site; University of Rochester Research Subjects
Review Board for the Rochester, NY site, University of
Maryland, School of Medicine IRB for the Baltimore, MD
(IHV) site; University of Kwazulu-Natal, Biomedical Research
Ethics Administration for the Klerksdorp, South Africa site;
University of Cape Town, Health Sciences Faculty Research
Ethics Committee for the Cape Town, South Africa site; and
University of the Witwatersrand, Johannesburg, Human Re-
search Ethics Committee for the Soweto, South Africa site. The
study was also approved by each country’s Regulatory agency
and was reviewed by the US Food and Drug Administration
before being allowed to proceed. All study participants provided
written informed consent prior to participation. The protocol for
this trial and supporting CONSRT checklist are available as
supporting information; see Protocol S1 and Checklist S1. The
trial is registered at ClinicalTrials.gov, registration NCT00
125970.
Study type, population and randomization
Participants were randomized 1:1 to placebo or vaccine and
followed for 12 months after enrollment. Randomization was done
by the Statistical Center for HIV/AIDS Research and Prevention
using computer generated random numbers stratified by geo-
graphic region and done in blocks to ensure balance across groups.
The study pharmacist maintained security of the randomization
list. All participants and study staff, apart from the study
pharmacist, were blinded to treatment assignment.
Eligibility criteria
Participants were eligible if between 18 and 50 years of age, in
good general health based on history, clinical examination and
laboratory investigations, practiced behaviors that placed them at
low or intermediate risk for HIV acquisition, had no history of
receiving investigational products, immunosuppressive medica-
tion, blood products, immunoglobulin or vaccines within study-
defined periods prior to enrollment. Female participants of
childbearing potential were not pregnant or planning to become
pregnant and agreed to consistently use contraception for 21 days
prior to their first vaccination until 9 months after first
vaccination.
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The DNA-HIV vaccine (VRC-HIVDNA-016-00-VP) was
manufactured by Vical Incorporated (San Diego, CA) and is
composed of six DNA plasmids in equal concentrations that
encode Gag, Pol, and Nef from clade B (strains HXB2, NL4-3,
NY5/BRU respectively) and HIV-1 Env glycoproteins from clade
A (strain 92rw020), clade B (strains HXB2/BaL), and clade C
(strain 97ZA012). The DNA placebo was sterile phosphate
buffered saline (PBS). Four mg of DNA-HIV or placebo were
delivered intramuscularly at 0, 1 and 2 months using the
BiojectorH 2000 Needle-Free Injection System.
The rAd5-HIV vaccine (VRC-HIVADV014-00-VP, rAd5) was
a replication-defective, vaccine containing a mixture of four rAd5
vectors in a 3:1:1:1 ratio that encode the HIV-1 Gag-Pol
polyprotein from clade B (strains HXB2-NL4-3) and HIV-1 Env
glycoproteins from clades A, B and C matching the DNA Env
components. The rAd5-HIV was manufactured by Molecular
Medicine (San Diego, CA) under contract to GenVec Incorpo-
rated (Gaithersburg, MD). The rAd5-HIV placebo was adenoviral
final formulation buffer (FFB, VRC-DILUENT013-DIL-VP), that
was also used as a diluent for the product. The rAd5-HIV or
placebo was delivered intramuscularly using a needle and syringe
at 6 months. The dose of rAd5-HIV was 10
10 PU.
Safety evaluation
Reactogenicity assessments were performed on all participants
for 3 days following each injection. Participants recorded symptoms
using a post-vaccination symptom log and were contacted daily by
the study site during this time. Reactogenicity was assessed on local
symptoms and signs at the injectionsite (pain, tenderness, erythema,
indurationand tendernessandenlargementofaxillarylymphnodes)
and systemic signs (body temperature) and symptoms (malaise and/
or fatigue, myalgia, headache, chills, arthralgia, nausea, vomiting).
All local and systemic signs, symptoms and laboratory measures of
safety were coded according to the Medical Dictionary for
Regulatory Activities terminology, and graded using the US
Division of AIDS Table for Grading the Severity of Adult and
Pediatric Adverse Events as mild, moderate, severe or potentially
life-threatening. Adverse events were assessed for their relationship
to study product.
Risk reduction counselling was provided at all study visits and
women of child bearing potential were advised to avoid pregnancy
for9 monthsafterthe lastvaccination. Participants wereadvisednot
to have HIV testing outside of the study. During the study HIV
status was determined using HIV-1 ELISA and HIV RNA PCR. At
the end of study, several licensed diagnostic HIV ELISA assays
(Abbot HIVAB HIV 1/2 [rDNA], BioRad Genetic System HIV 1/
2 Plus O EIA, BioRad Genetic System HIV 1/2 rLAV, bioMerieux
Vironostika HIV-1) were performed on sera from HIV-uninfected
participants to assess the false positive rate of each assay.
Immunogenicity analysis
Interferon-c (IFN-c) ELISpot assay. ELISpot assays were
performed on participants’ peripheral blood mononuclear cells
(PBMCs) cryopreserved within 8 hours of collection using a
standardized, validated, bulk IFN-c ELISpot assay [13] 6 weeks
after the fourth vaccination on all available specimens. Global and
Clade C potential T-cell epitope (PTE) [14] pools for HIV Env,
Gag, Pol and Nef were used at a final concentration of 1.0 mg/ml.
Intracellular cytokine staining assay
Intracellular cytokine staining (ICS) assays were performed
on cryopreserved PBMCs by flow cytometry using PBMCs to
determine both HIV-specific and Ad5-specific CD4+ and
CD8+ T-cell responses [15] at 6 weeks after the fourth
vaccination. For the detection of HIV-specific T cells, thawed
PBMC were cultured overnight and then stimulated for six
hours with the same HIV-1 peptide pools as for ELISpot
[13,16].
For the detection of Ad5-specific T cells, an ‘‘empty’’ vector
lacking HIV-1 gene inserts (provided by Dr. Gary Nabel, NIH
Vaccine Research Center, Bethesda, MD) was used to stimulate
PBMC. The Ad5 vector was added to PBMC cultures at a ratio of
10,000 Ad5 particle units per cell, six hours later the cells were
treated with Brefeldin A, and the ICS assay was performed after
an overnight incubation.
Initially eight-color [16] and then 10-color (once validated)
[13] ICS assays were used. Criteria for an evaluable response
and positivity were based on background measurements and the
number of CD4+ and CD8+ cells T cells examined [16]. The
frequency and magnitude of CD4+ and CD8+ T-cells producing
IFN-c or interleukin (IL)-2 in response to stimulation with
global PTE was reported. The degree of polyfunctionality was
evaluated by determining the percent of reactive CD4+ and
CD8+ T-cells that produced one or more cytokines (IFN-c,I L - 2
or TNF-a).
Binding antibodies
Serum HIV-1 specific IgG responses (1/20 dilution) against p55
Clade B Gag (Protein Sciences), Group M Consensus (Con S)
gp140 CFI, VRC Clade A gp140, VRC Clade B gp140 and
DU123 Clade C gp140 (provided by Dr. L. Liao and B. Haynes,
Duke University) were measured at four weeks after the fourth
vaccination by a standardized HIV-1 luminex assay as previously
described [17,18]. Antibody measurements were acquired on a
Bio-Plex instrument (Bio-Rad) and the readout was expressed as
mean fluorescent intensity (MFI). The positive control in each
assay was HIV positive sera and the negative control was HIV-
negative human sera and blank beads. Samples with blank bead
MFI.10,000 were excluded. Samples were determined to be
positive if both the MFI and MFI minus blank were greater than
3-fold over the baseline (study visit 2) MFI and MFI minus blank,
respectively, and the MFI minus blank was at least 732 MFI (based
on the average+3 standard deviations of 25 seronegative plasma
samples).
HIV-1 neutralization assay
Neutralizing antibodies against HIV-1 were measured as a
function of reduction in Tat-regulated luciferase (Luc) reporter
gene expression after a single round of infection in TZM-bl cells
that are permissive to infection to a wide range of HIV strains.
Serum and plasma samples were tested at four weeks after the
fourth vaccination for an ability to neutralize homologous vaccine
strains (92RW020.2, 97ZA012.29, Bal.26) and tier-1 strains that
are highly sensitive to neutralization (MN and SF162.LS) [19,20].
Assays are considered positive if the titer is $25. Antibodies that
neutralized tier 1 viruses were evaluated further to determine
whether they could neutralize a multi-subtype panel of tier 2
viruses. Serum samples from responders were screened at a 1:10
dilution for neutralizing activity against two subtype A viruses
(Q23.17, Q842.d12.), four subtype B viruses (QH0692.42,
SC422661.8, PVO.4, AC10.0.29) and four subtype C viruses
(Du156.12, Du172.17, Du422.1, ZM197M.PB7). As a control for
nonspecific activity, the samples were also assayed against a
pseudovirus containing the envelope glycoproteins of murine
leukemia virus (MLV).
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Samples could not be included in the immunogenicity analysis
if: there was insufficient sample quantity; the sample could not be
located at the repository; the sample was not collected or collected
out of the visit window; the participant was terminated from the
study or was HIV-infected at the time of the blood draw.
Statistical methods
The sample size of 240 vaccine and 240 placebo recipients per
group allowed a robust characterization of safety and immuno-
genicity. Specifically, the sample size of 240 in the vaccine group
provided a 90% chance of observing at least one serious adverse
event if the true rate of such an event were at least 1%. After
accounting for a 10% dropout rate, the sample size of the vaccine
group (n=216) allows a reasonably precise estimate of the
immune response rate, with a maximum 95% confidence interval
(CI) width of 14%.
To summarize the T-cell response data, positive response rates to
any peptide pool and to each individual protein were reported.
Positivity of the individual IFN-c ELISpot responses was deter-
mined by a one-sided bootstrap test of the null hypothesis that the
experimental well responses were twice those of the background
(a=0.05) [21]. A Westfall-Young approach was used to adjust for
the multiple comparisons across peptide pools. Peptide pools with
adjusted one-sided p-values#0.05 were declared positive. In
addition, the mean difference in the experimental and negative
control wells had to exceed 50 SFC per 10
6 PBMC for the response
to be positive. Positivity of the ICS responses was determined by a
Figure 1. Number of individuals enrolled, randomized to vaccine or placebo, followed-up and analyzed. ICS=Intracellular cytokine
staining, Ad5=Adenovirus serotype 5.
doi:10.1371/journal.pone.0021225.g001
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response versus the negative control response with a discrete
Bonferroni adjustment for the multiple comparisons. Peptide pools
with adjusted p-values less than a=0.00001 were considered
positive. Confidence intervals for response rates were calculated
with the score test method [22]. Response rates were compared by
two-sided Fisher’s exact tests. Generalized estimating equations
(GEE) for binary data with an unstructured correlation matrix were
used to model local and systemic reactionrates separately over time.
A GEE model with time, treatment, and a treatment*time
interaction term was used to evaluate whether the longitudinal
trend inreaction rates differedbetween vaccine andplacebo groups.
McNemar’s tests were used to compare the CD4+ and CD8+
response rates to the empty Ad5 vector in vaccine and placebo
recipients separately. SAS (Version 9.1; SAS Institute) and R
(Version 2.11.1) were used for all analyses. The analysis comparing
HIV-specific CD4+ and CD8+ T-cell responses by baseline Ad5
status was restricted to U.S. participants only as they had the largest
proportion of Ad5 seronegative vaccine recipients and the most
complete ICS data available.
Results
The number of individuals enrolled and randomized to vaccine
or placebo, followed-up and analyzed are shown in Figure 1.
Between July 2006 and December 2007, 480 participants were
enrolled and followed up: 240 were enrolled in South Africa and
240 were enrolled in the Americas (n=180 in the United States
and n=60 in Latin America and Caribbean [Jamaica, Haiti and
Brazil]). Of the 240 vaccine and placebo recipients, 206 (85.8%)
and 207 (86.3%) participants completed all vaccinations and study
visits. The baseline characteristics of the cohort are summarized in
Table 1. The vaccine and placebo arms were similar with respect
to geographic region, age, gender, ethnic group, sexual orienta-
tion, pre-existing Ad5 neutralizing antibodies and the percent
completing vaccinations and all study visits.
Safety
Injection site reactions ($mild) were more common in DNA-
HIV and rAd5-HIV vaccine recipients than placebo recipients
(DNA-HIV: 86.3% vs 67.5%, p,0.001; Ad5-HIV: 49.8% vs
Table 1. Cohort characteristics.
Placebo (N=240) Vaccine (N=240)
Geographic region United States 90 (37.5%) 90 (37.5%)
South Africa 120 (50%) 120 (50%)
Latin America & Caribbean 30 (12.5%) 30 (12.5%)
Median age (range) (yrs) 26.0 (18–50) 25.0 (18–50)
Female (%) 127 (53%) 127 (53%)
Ethnic group (%) White 58 (24%) 58 (24%)
Black 161 (67%) 162 (68%)
Hispanic 16 (7%) 14 (6%)
Other 5 (2%) 11 (5%)
Sexual orientation Heterosexual 210 (88%) 212 (88%)
Homosexual 20 (8%) 22 (9%)
Bisexual 10 (4%) 6 (3%)
Pre-existing Ad5 Nab titer* ,12
United States 24 (27%) 38 (42%)
South Africa 8 (7%) 4 (3%)
Latin America & Caribbean 3 (10%) 4 (13%)
.12
United States 66 (73%) 52 (58%)
South Africa 105 (88%) 109 (91%)
Latin America & Caribbean 27 (90%) 26 (87%)
Missing
United States 0 (0%) 0 (0%)
South Africa 7 (6%) 7 (6%)
Latin America & Caribbean 0 (0%) 0 (0%)
Number vaccinated Month 0 (DNA/placebo) 240 (100%) 240 (100%)
Month 1 (DNA/placebo) 234 (98%) 231 (96%)
Month 2 (DNA/placebo) 228 (95%) 224 (93%)
Month 6 (Ad5/placebo) 216 (90%) 213 (89%)
HIV infections 4 (1.7%) 3 (1.3%)
Latin America & Caribbean (Brazil, Jamaica, Haiti),
*Expressed as the proportion for each region.
doi:10.1371/journal.pone.0021225.t001
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each subsequent dose of DNA or placebo (p,0.0001) with no
effect modification by treatment (p=0.06). Maximal systemic
symptoms and signs ($mild) did not differ between DNA-HIV
and placebo recipients overall (p=0.582) but were significantly
more common in rAd5-HIV vaccine than placebo recipients
(38.0% vs 13.4%, p,0.001) (Figure 2B). Systemic reactions also
decreased with each subsequent dose of DNA or placebo
(p,0.0001) with no effect modification by treatment (p=0.40).
Detailed monitoring showed that the number of DNA-HIV and
rAd5-HIV vaccine recipients that had one or more adverse events
was similar to that of placebo recipients. Signs and symptoms of
upper respiratory tract infections and headache were the most
frequent adverse events in DNA-HIV recipients (Table 2). There
were no significant alterations in liver function tests and white
blood cell counts in rAd5-HIV vaccine compared to placebo
recipients (Table 2). Of the 9 pregnancies that occurred in the
placebo arm, there were two elective and one spontaneous
abortion and six healthy infants born. Of the 7 pregnancies in the
vaccine arm, there were four elective abortions, 2 healthy infants
born, and the outcome of one pregnancy was unknown. Four
placebo and three vaccine recipients became HIV-infected during
the 12 month study follow up period, all in the South African
cohort. One vaccinee and two placebo recipients were found to be
HIV positive after terminating the study based on a sample
collected at the Month 12 study visit. The vaccine commonly
produced antibodies to HIV proteins after the rAd5 boost; 87.9%
([204/232], 95% CI 83.1%–91.5%) of recipients had a false
positive HIV-1 test to at least one of the diagnostic HIV ELISAs
used.
T-cell responses detected by IFN-c ELISpot
Six weeks after the rAd5-HIV boost, the percent of participants
with detectable T-cell responses by IFN-c ELISpot, using global
PTE peptides, to any antigen among placebo and vaccine
recipients was 3.1% (6/194) and 70.8% (136/192), respectively
(p,0.01) (Table 3). Responses were observed for all antigens, but
most frequently to Gag (54.7%) and Env (54.2%), and did not
differ by geographical region (Table 3). Among the 136 vaccine
recipients with positive responses, 30.9%, 33.8%, 28.7% and 6.6%
had responses to 1, 2, 3 and 4 genes, respectively, with the most
frequent combination of responses to Env/Gag (23.5%), Env/
Gag/Pol (19.1%), Env only (14.0%) and Gag only (14.0%). The
median magnitude of response (SFC/10
6 PBMC) were: any
antigen 408; Env 177; Gag 171; Nef 120 and Pol 134 (Figure 3).
In contrast to Ad5-seronegative subjects, a smaller proportion of
U.S. subjects who had Ad5 neutralizing antibodies (Ad5 NAb) at
baseline had positive T-cell responses for any antigen (62.5% vs.
85.7%, p=0.035), Env (50% vs. 62.9%, p=0.352), Gag (47.5%
vs. 74.3%, p=0.021) and Pol (12.5% vs. 40.0%, p=0.008); the
placebo response rate was 1.4% (1/74) overall. Not unexpectedly,
responses to Nef were similar (15.0% vs. 11.4%, p=0.742) as Nef
was not included in the rAd5-HIV vaccine (Table 4). The median
magnitude (SFC/10
6 PBMC) of responses were slightly lower
among Ad5 seropositive versus seronegative participants for any
antigen (513 versus 560), Env (167 versus 239), Gag (250 versus
259) and Nef (100 versus 120) but was higher for Pol (200 versus
110) (Figure 3).
Intracellular cytokine staining responses
CD4+ and CD8+ T-cell IFN-c and/or IL2 responses. A
similar frequency of vaccine recipients had HIV-specific CD4+ (56/
134=41.8%) and CD8+ (76/161=47.2%) T-cell responses
producing IL-2 and/or IFN-c in response to at least one peptide
pool (Table 3). Among 130 vaccine recipients with concurrent
CD4+ and CD8+ T-cell responses to at least one antigen, 16.9%
(22/130) had CD4+ and CD8+ T-cell responses to the same
antigen, that is Env, Gag, Nef or Pol. The distribution of responses
to individual antigens was however different for each T-cell: the
highest frequency of CD4+ responses were to Gag (34.3%) and Env
(21.6%) and there were no responses to Pol; the highest frequency
CD8+ T-cell responses were seen to Env (32.3%) and Pol (15.5%).
U.S. vaccine recipients who were Ad5 seropositive versus
seronegative had lower response rates, particularly for CD8+ T
cells (CD4: 46.2% vs. 55.2%, p=0.624; CD8: 42.1% vs. 67.9%,
p=0.048), which was consistent for all antigens (Table 4). The
median magnitude of CD4+ and CD8+ T-cell responses were
similar (Figure 3) but the antigen specificity differed by T-cell type:
the greatest median magnitude of CD4+ T-cell response was to
Gag; the median magnitude of CD8+ T-cell responses were similar
for all antigens. Among Ad5 seropositive versus seronegative U.S.
participants the median magnitude of CD4+ responses (percent
positive) were slightly lower for all antigens (Env: 0.11 vs. 0.14; Gag:
0.17 vs. 0.18; Nef: 0.08 vs. 0.11). Similarly the median magnitude of
CD8+ T-cells responses were lower in seropositive U.S. participants
(Gag: 0.22 vs.0.32; Nef: 0.08 vs. 0.14; Pol: 0.11 vs. 0.16) apart from
Env (0.22 and 0.24) (Figure 3).
Polyfunctionality of CD4+ and CD8+ T-cells. The propor-
tion of vaccine recipients with CD4+ and CD8+ reactive T-cells to
PTE peptides that produced one or more cytokines (IFN-c, IL-2,
TNF-a) are shown in Figure 4. The proportion who had CD4+
T-cells producing one, two or three cytokines was similar. Among
Figure 2. Maximal local and systemic reactogenicity after each
vaccination. Frequency of local (A) and systemic (B) reactions
occurring within three days following each DNA and rAd5 vaccination.
Local injection site reactions included pain, tenderness, erythema and
induration. Systemic reactions included malaise/fatigue, headache,
chills, myalgia, arthralgia or increased body temperature. P=Placebo,
V=Vaccine.
doi:10.1371/journal.pone.0021225.g002
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DNA vaccine or placebo. Vaccine (n=240) Placebo (n=240)
N( % ) N( % )
Total with one or more adverse events 177 (73.8%) 172 (71.7%)
Upper respiratory tract infection 38 (15.8%) 31 (12.9%)
Headache 16 (6.7%) 14 (5.8%)
Nasopharyngitis 14 (5.8%) 9 (3.8%)
Neutrophil count decreased 9 (3.8%) 3 (1.3%)
Lymphadenopathy 8 (3.3%) 3 (1.3%)
Pharyngitis 8 (3.3%) 2 (0.8%)
Proteinuria 8 (3.3%) 3 (1.3%)
Haematuria 7 (2.9%) 6 (2.5%)
Diarrhoea 5 (2.1%) 4 (1.7%)
Injection site pruritus 5 (2.1%) 0 (0.0%)
Toothache 5 (2.1%) 3 (1.3%)
Anaemia 4 (1.7%) 0 (0.0%)
Blood pressure increased 4 (1.7%) 3 (1.3%)
Cough 4 (1.7%) 1 (0.4%)
Dermatitis contact 4 (1.7%) 1 (0.4%)
Epistaxis 4 (1.7%) 2 (0.8%)
Influenza 4 (1.7%) 1 (0.4%)
Injection site swelling 4 (1.7%) 1 (0.4%)
Weight decreased 4 (1.7%) 2 (0.8%)
Dermatitis 3 (1.3%) 2 (0.8%)
Excoriation 3 (1.3%) 0 (0.0%)
Furuncle 3 (1.3%) 0 (0.0%)
Lower respiratory tract infection 3 (1.3%) 1 (0.4%)
Menorrhagia 3 (1.3%) 0 (0.0%)
Sexually transmitted disease 3 (1.3%) 0 (0.0%)
Stomach discomfort 3 (1.3%) 0 (0.0%)
Tooth abscess 3 (1.3%) 2 (0.8%)
Urticaria 3 (1.3%) 1 (0.4%)
Vomiting 3 (1.3%) 2 (0.8%)
rAd5 vaccine or placebo Vaccine (n=213) Placebo (n=216)
Total with one or more adverse events 148 (69.5%) 151 (69.9%)
Alanine aminotransferase increased 17 (8.0%) 10 (4.6%)
Nasopharyngitis 11 (5.2%) 11 (5.1%)
Weight decreased 9 (4.2%) 2 (0.9%)
Neutropenia 7 (3.3%) 6 (2.8%)
Neutrophil count decreased 6 (2.8%) 5 (2.3%)
Anaemia 5 (2.3%) 4 (1.9%)
Vaginal candidiasis 5 (2.3%) 4 (1.9%)
Pain in extremity 4 (1.9%) 1 (0.5%)
Viral infection 4 (1.9%) 2 (0.9%)
Abdominal pain lower 3 (1.4%) 0 (0.0%)
Diarrhoea 3 (1.4%) 1 (0.5%)
Otitis media 3 (1.4%) 0 (0.0%)
Sinusitis 3 (1.4%) 2 (0.9%)
Subcutaneous abscess 3 (1.4%) 1 (0.5%)
Vomiting 3 (1.4%) 0 (0.0%)
doi:10.1371/journal.pone.0021225.t002
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IL-2 and IL-2/TNF-a were produced most often. Most CD8+
reactive T-cells produced only one or two cytokines. Among single
and double-cytokine-producing CD8+ T-cells, IFN-c and IFN-c/
TNF-a were produced most often. Among U.S. participants, the
proportion of CD4+ and CD8+ responsive T-cells that produced
one or more cytokine did not differ by Ad5 Nab status (data not
shown).
Ad5 vector T-cell responses. IL-2 and/or IFN-c ICS
responses six weeks after the Ad5 boost to the empty Ad5
Table 3. Frequency of interferon-c T cell ELISpot, intracellular cytokine staining, binding and neutralizing antibody and Ad5 vector
responses.
Placebo Vaccine
N % 95% CI N % 95% CI
IFN-c ELISpot* Overall 194 3.1 1.4–6.6 192 70.8 64.0–76.8
Region
LAC 23 4.3 0.8–21.0 24 70.8 50.8–85.1
USA 74 1.4 0.2–7.3 75 73.3 62.4–82.0
South Africa 97 4.1 1.6–10.1 93 68.8 58.8–77.3
Antigen
Env 194 2.1 0.8–5.2 192 54.2 47.1–61.1
Gag 194 0.5 0.1–2.9 192 54.7 47.6–61.6
Nef 194 0.0 0.0–1.9 192 17.2 12.5–23.2
Pol 194 0.5 0.1–2.9 192 23.4 18.0–29.9
Intracellular Cytokine Staining* CD4
Overall 144 4.9 2.4–9.7 134 41.8 33.8–50.3
Env 144 3.5 1.5–7.9 134 21.6 15.5–29.4
Gag 144 1.4 0.4–4.9 134 34.3 26.8–42.7
Nef 144 0.0 0.0–2.6 134 6.7 3.6–12.3
Pol 144 0.0 0.0–2.6 134 0.0 0.0–2.8
CD8
Overall 167 2.4 0.9–6.0 161 47.2 39.6–54.9
Env 167 1.8 0.6–5.1 161 32.3 25.6–39.9
Gag 165 0.6 0.1–3.4 159 13.8 9.3–20.1
Nef 167 0.0 0.0–2.2 161 8.7 5.3–14.1
Pol 167 0.0 0.0–2.2 161 15.5 10.7–21.9
Ad5 vector responses*
Any 115 51.3 42.3–60.2 116 75.0 66.4–82.0
CD4 92 62.0 51.7–71.2 92 83.7 74.8–89.9
CD8 115 13.9 8.7–21.4 116 37.9 29.6–47.0
Binding antibody responses** gp140 Con S 209 1.0 0.3–3.4 202 94.6 90.5–96.9
gp140 Clade C 209 0 0.0–1.8 202 93.1 88.7–95.8
gp140 Clade A 209 0 0.0–1.8 202 83.7 77.9–88.1
gp140Clade B 209 0 0.0–1.8 202 94.6 90.5–96.9
gp41 209 0.5 0.1–2.7 202 93.1 88.7–95.8
P55 209 1.0 0.3–3.4 202 45.5 38.8–52.4
Neutralizing antibody responses** 92RW020.2 218 0.0 0.0–1.7 220 0.0 0.0–1.7
97ZA012.29 218 0.0 0.0–1.7 220 0.0 0.0–1.7
Bal.26 218 0.0 0.0–1.7 220 0.9 0.2–3.3
MN 218 5.0 2.8–8.8 220 18.6 14.0–24.3
SF162.LS 218 0.0 0.0–1.7 220 7.7 4.9–12.0
All responses are to Global PTE peptide pools.
*6 weeks after Ad5 boost,
**4 weeks after rAd5 boost. USA=United States of America. LAC=Latin America and Caribbean. N’s refer to number of samples with evaluable data (that passed all
quality control filters). ELISpot assays were run on 209 placebos (P) and 205 vaccinees (V): Latin America: 24 P, 24 V; USA: 81 P, 80 V; South Africa: 104 P, 101 V. CD4 and
CD8 ICS assays were run on 175 P and 167 V; Ad5 vector ICS assays were run on 115 P and 116 V. Neutralizing antibody assays were run on 220 P and 222 V. Luminex
binding antibody assays were run on 219 P and 206 V.
doi:10.1371/journal.pone.0021225.t003
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PLoS ONE | www.plosone.org 8 August 2011 | Volume 6 | Issue 8 | e21225Figure 3. Magnitude of T-cell responses recognizing global PTEs 6 weeks after the Ad5 boost in all participants and by Ad5 titer in
US participants. Shown are the magnitude of T-cell responses as measured by IFN-c ELISpot responses (A) and percentage of CD4+ (B) and CD8+
(C) T-cells producing interferon-c and/or interleukin-2 in response to Env, Gag, Pol or Nef six weeks after rAd5 boost in all participants (left) and in
United States participants stratified by adenovirus serotype-5 titer (,12, $12, right). Only the Ad5 data for US participants is shown as they had the
highest proportion of participants who were Ad5 negative at baseline. Positive responders are shown in red and negative responders in blue. The
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to placebo (n=115) recipients overall (75% versus 51.3%,
p,0.001) (Table 3). A significantly greater proportion of
CD4+ compared to CD8+ reactive T cells responded to the
empty Ad5 vector in vaccine (83.7% versus 37.9%,
respectively, p,0.0001) and placebo (62.0% versus 13.9%,
respectively, p,0.0001) recipients. The magnitude of reactive
CD4+ and CD8+ T-cell responses to the empty rAd5 vector
were similar in vaccine and placebo recipients (Figure 5).
Among vaccine and placebo recipients enrolled in the U.S. the
frequency and magnitude of responses to the empty rAd5
vector were similar in Ad5 seronegative and seropositive
participants (Table 4, Figure 5), indicating that the Ad5-
specific T-cell responses were influenced by previous exposure
to other adenovirus serotypes and cross reactive responses to
these serotypes.
Binding and neutralizing antibody responses
A very high frequency of binding antibody responses were
observed to Con S (94.6%), Clade A (83.7%), Clade B (94.6%) and
Clade C (93.1%) gp140 oligomers and to gp41 (93.1%); and
moderate responses to p55 (45.5%) (Table 3).
Neutralizing antibody (NAb) assays were performed for 218 and
220 placebo and vaccine recipients, respectively. There were no
Nab responses detected to 92RW020.2 and 97ZA012.29 isolates.
The greatest frequency of responses was to MN (18.6%),
SF162.LS (7.7%) and Bal.26 (0.9%) Tier 1 viruses (Table 3).
Despite potent neutralizing activity against MN and SF162.LS
boxplots show the distribution of responses in positive responders only. The box indicates the median and inter-quartile range; whiskers extend to
1.5 times the inter-quartile range from the upper or lower quartile. The numbers above the graphs indicate the number positive relative to the total
number examined and the corresponding percentage positive.
doi:10.1371/journal.pone.0021225.g003
Table 4. Frequency of ELISpot, CD4 and CD8 T-cell ICS responses 6 weeks after Ad5 boost among US participants, stratified by pre-
existing Ad5 NAb titer.
Pre-existing Ad5 nAb titer ,12 Pre-existing Ad5 nAb titer $12
Placebo Vaccine Placebo Vaccine
% 95%CI % 95%CI % 95%CI % 95%CI
IFN-c ELISpot
N=20 N=35 N=54 N=40
Overall 5.0% 0.9%–23.6% 85.7% 70.6%–93.7% 0.0% 0.0%–6.6% 62.5% 47.0%–75.8%
Antigen
Gag 0.0% 0.0%–16.1% 74.3% 57.9%–85.8% 0.0% 0.0%–6.6% 47.5% 32.9%–62.5%
Pol 5.0% 0.9%–23.6% 40.0% 25.6%–56.4% 0.0% 0.0%–6.6% 12.5% 5.5%–26.1%
Nef 0.0% 0.0%–16.1% 11.4% 4.5%–26.0% 0.0% 0.0%–6.6% 15.0% 7.1%–29.1%
Env 0.0% 0.0%–16.1% 62.9% 46.3%–76.8% 0.0% 0.0%–6.6% 50.0% 35.2%–64.8%
Intracellular Cytokine Staining
CD4+ N=21 N=29 N=55 N=39
Overall 0.0% 0.0%–15.5% 55.2% 37.5%–71.6% 5.5% 1.9%–14.9% 46.2% 31.6%–61.4%
Antigen
Gag 0.0% 0.0%–15.5% 44.8% 28.4%–62.5% 3.6% 1.0%–12.3% 30.8% 18.6%–46.4%
Pol 0.0% 0.0%–15.5% 0.0% 0.0%–11.7% 0.0% 0.0%–6.5% 0.0% 0.0%–9.0%
Nef 0.0% 0.0%–15.5% 6.9% 1.9%–22.0% 0.0% 0.0%–6.5% 5.1% 1.4%–16.9%
Env 0.0% 0.0%–15.5% 37.9% 22.7%–56.0% 1.8% 0.3%–9.6% 30.8% 18.6%–46.4%
CD8+ N=21 N=28 N=54 N=38
Overall 0.0% 0.0%–15.5% 67.9% 49.3%–82.1% 0.0% 0.0%–6.6% 42.1% 27.9%–57.8%
Antigen
Gag 0.0% 0.0%–15.5% 28.6% 15.3%–47.1% 0.0% 0.0%–6.6% 15.8% 7.4%–30.4%
Pol 0.0% 0.0%–15.5% 28.6% 15.3%–47.1% 0.0% 0.0%–6.6% 13.2% 5.8%–27.3%
Nef 0.0% 0.0%–15.5% 7.1% 2.0%–22.6% 0.0% 0.0%–6.6% 7.9% 2.7%–20.8%
Env 0.0% 0.0%–15.5% 42.9% 26.5%–60.9% 0.0% 0.0%–6.6% 31.6% 19.1%–47.5%
Ad5 vector* N=12 N=22** N=37** N=24**
Overall 91.7% 64.6%–98.5% 95.5% 78.2%–99.2% 83.8% 68.9%–92.3% 87.5% 69.0%–95.7%
CD4+ 91.7% 64.6%–98.5% 90.5% 71.1%–97.3% 86.1% 71.3%–93.9% 87.0% 67.9%–95.5%
CD8+ 25.0% 8.9%–53.2% 40.9% 23.3%–61.3% 24.3% 13.4%–40.1% 54.2% 35.1%–72.1%
*Overall CD4+ and CD8+ T cell ICS responses to the empty Ad5 vector,
**Data missing for one participant for CD4+ T-cell responses.
doi:10.1371/journal.pone.0021225.t004
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2 viruses (data not shown).
Discussion
This study of the VRC multigene, multiclade DNA-HIV prime,
rAd5-HIV boost vaccine regimen showed that the vaccines were
well tolerated, safe and immunogenic. T-cell immunogenicity of
the vaccine regimen, as measured by the IFN-c ELISpot assay,
was consistent with those reported from the IAVI V001 trial in
Kenya and Rwanda and the URMHRP RV172 trial in Kenya,
Tanzania and Uganda [11,12]. In addition, our study provides a
more in-depth look at HIV-specific immune responses using the
ICS assay, as well as contrasting these data with that directed
towards the rAd5 vector itself.
The results from two recent preventive HIV vaccine efficacy
trials provide important insights into what may be required to
develop an effective HIV-1 vaccine. The RV144 trial in Thailand
showed modest efficacy of the recombinant canarypox vector
vaccine (ALVAC-HIV) prime, which expresses subtype E gp120,
and the ALVAC-HIV and AIDSVAX subtype B/E gp120 subunit
vaccine boost in a cohort that was at relatively low-risk for
heterosexual HIV acquisition. That study has highlighted the
potential importance of inducing Env-specific antibodies in the
protection against HIV infection [2,23,24], even those lacking
classical neutralizing activity. The extent to which having both
Env and internal antigens in the vaccine preparation, the role of
HIV-specific CD4+ versus CD8+ T-cell responses and a study
population with a relatively low HIV incidence is the subject of
ongoing investigation. In contrast, the phase IIB study of the
replication-defective Merck rAd5-vectored vaccine (Merck 023/
HVTN 502; the STEP Study) composed of clade B Gag, Nef and
Pol (without Env) and given at 0, 1 and 6 months to high-risk men
who have sex with men and women was stopped prematurely
when a pre-defined futility criteria was met and there was no
evidence that the vaccine provided protection against HIV
infection or reduced viral load among infected participants,
despite frequent and strong CD8+ T-cell responses to vaccine
specific antigens [13].
Nevertheless, in sub-studies evaluating subjects with selected
HLA types [25] and in an intensive sequence analysis of
breakthrough HIV isolates [26] there was evidence of a CD8 T-
cell effect. Subjects with HLA-B27, HLA-B57, or HLA-B5801
who were vaccinated had significantly lower viral loads than
placebo recipients bearing the same alleles [25]. Similarly,
comparing breakthrough viruses from vaccinees and placebo
recipients there was a conspicuous signature sequence in Gag aa84
that involves a number of overlapping MHC class I-restricted
epitopes [26].
Similar to the RV144 ALVAC/AIDSVAX HIV vaccine
regimen the VRC DNA-HIV prime, rAd5-HIV boost regimen
included Env and induced Env-specific binding antibody respons-
es to the vaccine strain antigens [24]. Binding antibody responses
to the VRC vaccine strain envelopes were of similar or higher
magnitude compared to the vaccine elicited antibody responses in
RV144. However, additional assays will be needed to determine
Figure 4. Polyfunctional CD4+ and CD8+ T-cell IFN-c, TNF-a and IL2 cytokine responses. The left graphs show the percentage of the HIV-
specific CD4+ (upper panel) or CD8+ (lower panel) T-cells that are producing one, two or three cytokines in the vaccine recipients. Intracellular
cytokine staining analyses were done on PBMC obtained six weeks after the rAd5 boost. The right graphs depict the percentage of cells producing
interferon-c, interleukin-2 or tumor necrosis factor-a in those cells producing one cytokine (middle panels), and the percentage of cells co-producing
two cytokines (panels on the right). The boxplots show the distribution of responses in positive responders only. The box indicated the median and
inter-quartile range; whiskers extend to 1.5 times the inter-quartile range from the upper or lower quartile.
doi:10.1371/journal.pone.0021225.g004
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response, in terms of antibody specificity, avidity and functional
anti-viral properties of the vaccine elicited responses in HVTN
204 compared to RV144. If antibody correlates of protection are
identified in the future analysis of RV144, these assays could be
applied to samples from this study.
The vaccine regimen evaluated in this study induced compa-
rable CD8 T-cell response magnitude and quality compared to the
responses induced by the Merck rAd5-HIV vaccine. However,
there are differences in antigen content, rAd5 vector construction,
and vaccine regimen that may influence the specificity and
breadth of the immune response. The VRC rAd5 expresses Env
antigens in addition to Gag and Pol and has deletions in E3, E4 as
well as E1 adenovirus genes that prevent production of adenovirus
structural proteins, thus focusing the antigen presentation
machinery on the vaccine antigen instead of the vector. In
addition, compared to the vaccine studied in the RV144 trial, the
VRC regimen induces a greater frequency and magnitude of HIV-
specific CD8+ T-cell responses [13,24,27].
South African participants in the HVTN204 trial had a very
high prevalence of pre-existing Ad5 Nabs titers (89%), which is
similar to other studies from Central and East Africa [11,12]. In
contrast, a far lower proportion of US participants were Ad5 sero-
positive (66%) at baseline, which is in keeping with other studies
[28]. Neither the USMHRP RV172 nor IAVI V001 trials showed
that the frequency of T-cell responses in African participants
vaccinated with the VRC DNA-HIV prime/rAd5-HV boosts
differed by baseline Ad5 NAb status [11,12]. In the RV172 trial
there was a non-significant trend to lower magnitude of IFN-c
ELISPOT responses in participants with higher baseline Ad5
titers. In contrast to RV172 and V001, the HVTN204 trial
provides strong evidence that pre-existing Ad5 NAb results in a
Figure 5. Magnitude of CD4+ and CD8+ T cell ICS responses to empty Ad5 vector. Percentage of CD4+ (top panels) and CD8+ T cells
(bottom panels) producing interferon-c and/or interleukin 2, or both, by intracellular cytokine staining, in response to Ad5 empty vector stimulation
in all (left panels) or US only (right panels) placebo and vaccine recipients 6 weeks after the Ad5 boost. Positive responders are shown in red and
negative responders in blue. The box plots and numbers above the graphs are as in Figure 2.
doi:10.1371/journal.pone.0021225.g005
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CD8+ T-cell ICS responses to Env, Gag and Pol but not Nef,
which was not included in the rAd5 boost. Of interest, the
frequency of CD4+ T-cell responses to the Ad5 vector were twice
that of the responses to the HIV gene inserts, whereas CD8+ T-
cell responses to the Ad5 vector and HIV gene inserts were similar.
The biological basis for this finding is not clear.
Thus, because pre-existing immunity to Ad5 in the developing
world is moderately high, strategies to overcome pre-existing
neutralizing antibodies from natural Ad5 infection are being
explored. Natural infection with Ad5 and rAd5 vaccination induce
different patterns of neutralizing antibody response, with natural
infection eliciting both fiber and capsid-specific responses and
vaccination eliciting more exclusively capsid-specific responses
[29]. Use of chimeric adenovirus vectors or rare serotype
adenovirus vectors, may avoid the impact of pre-existing immunity
to the vector.
The results from this and other studies have shown that the
VRC multi-clade DNA-HIV prime, rAd5-HIV boost regimen is
safe and, like the RV144 ALVAC/AIDSVAX HIV vaccine
regimen, induces a high frequency of Env-specific binding
antibodies [8,27] with poor and low levels of neutralizing activity.
The VRC vaccine regimen also induces: durable, concurrent,
polyfunctional CD4+ and CD8+ T-cell responses specific for
multiple HIV antigens [8,12]; and central memory and effector
CD8+ T cell responses with antiviral activity, which may play a
role in preventing infection and controlling chronic infection
[12,30,31]. However, antigen specific T-cell responses are reduced
in Ad5 Nab seropositive individuals. A limitation of this study is
that the effect of pre-existing Ad5 Nabs on HIV-specific T-cell
responses was not determined for all participants. These data were
important for supporting the initiation of a test of concept study of
the DNA-HIV prime, rAd5-HIV boost regimen in HVTN 505,
but because of the findings of the STEP Study, the study
population was limited to circumcised, Ad5 seronegative men in
the U.S. Recently, based on the immunogenicity data from
HVTN 204 and the RV144 studies and recent findings showing
that non-human primates immunized with the DNA/rAd5
platform were protected from repeated mucosal SIV challenge
[32], HIV acquisition has been added as a primary endpoint in the
ongoing HVTN 505 study.
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